AstraZeneca PLC (NYSE:AZN) is paying $600 million upfront to secure global rights to Zegfrovy from Dizal Pharmaceutical Co., Ltd, adding another targeted therapy to one of the pharmaceutical industry’s largest oncology portfolios. Dizal Pharmaceutical could receive an additional $900 million if specified development, regulatory, and sales milestones are achieved, bringing the agreement’s potential value to $1.5 billion. Dizal will also receive tiered royalties on the global sales of Zegfrovy.
Zegfrovy, also known as sunvozertinib, is an oral treatment approved in the United States and China for certain adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Under the agreement, AstraZeneca (NYSE:AZN) will take responsibility for the treatment’s global development and commercialisation.
For AstraZeneca (NYSE:AZN) shareholders, the transaction offers an opportunity to assess whether another targeted lung-cancer medicine can reinforce the company’s oncology leadership, or whether the price adds further execution risk to an already extensive pipeline.
Bull Case
The agreement strengthens AstraZeneca’s (NYSE:AZN) position in a therapeutic area where it already has substantial scientific and commercial experience. The company has built a major lung-cancer business around treatments including Tagrisso, Imfinzi, and Enhertu. That existing infrastructure could help AstraZeneca (NYSE:AZN) introduce Zegfrovy to physicians and patients more efficiently than a smaller developer with a limited global presence.
Zegfrovy also addresses a specific group of patients with EGFR exon 20 insertion mutations, for whom treatment options remain limited. In the Phase III WU-KONG28 trial, Zegfrovy produced median progression-free survival of 10.3 months, compared with 7.5 months for chemotherapy. AstraZeneca (NYSE:AZN) therefore gains an approved medicine supported by late-stage comparative evidence rather than an early experimental asset whose clinical viability remains largely unknown.
The transaction could also accelerate the drug’s international expansion. Zegfrovy is approved in the United States and China, but AstraZeneca’s (NYSE:AZN) global regulatory and commercial capabilities may create opportunities in additional markets. Dizal reported approximately $85 million or 576 million yuan in Zegfrovy revenue during 2025, an increase of roughly 85% from the previous year, demonstrating that the medicine had already begun generating commercial sales before the agreement.
Finally, the deal supports AstraZeneca’s (NYSE:AZN) goal of reaching $80 billion in annual revenue by 2030. Oncology delivered double-digit growth at constant exchange rates during the first half of 2026, and adding another targeted treatment could help sustain that momentum if Zegfrovy expands geographically and gains adoption.
Bear Case
The potential $1.5 billion consideration is substantial for a treatment that generated approximately $85 million in 2025. Although only $600 million is payable upfront, the valuation assumes that AstraZeneca (NYSE:AZN) can expand the medicine considerably beyond its existing commercial base.
The addressable population is also narrower than the overall lung-cancer market. Zegfrovy is designed for tumours carrying a specific and relatively uncommon EGFR mutation, limiting the number of eligible patients. The drug could become important within that group without producing revenue comparable to AstraZeneca’s (NYSE:AZN) largest oncology franchises.
Uncertainty also remains around the company’s international plans. When the agreement was announced, AstraZeneca (NYSE:AZN) did not provide details about additional global trials or future regulatory submissions. Investors therefore cannot yet determine how quickly the medicine could enter more markets or how much further development spending may be required.
The deal also adds another asset to an already extensive oncology pipeline. AstraZeneca (NYSE:AZN) must allocate clinical, regulatory, and commercial resources effectively, as acquiring a promising medicine does not immediately guarantee that it will achieve broad adoption in a competitive treatment market.
Conclusion
The Zegfrovy agreement is strategically consistent with AstraZeneca’s (NYSE:AZN) oncology-led growth model. The company is gaining an approved, revenue-generating medicine with positive Phase III data and could use its global lung-cancer infrastructure to expand the treatment beyond its existing markets.
Nevertheless, the commercial opportunity must justify a potential $1.5 billion commitment. Zegfrovy targets a narrowly defined patient population, and AstraZeneca (NYSE:AZN) has not disclosed a global development timetable or revenue forecast. The transaction strengthens its oncology portfolio, but its investment value will depend on whether AstraZeneca (NYSE:AZN) can convert a specialised treatment into a meaningfully larger global franchise.
While we acknowledge the risk and potential of AZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center